IPOs

Four years after mega IPO, Circassia set for small-cap exchange
Four years after mega IPO, Circassia set for small-cap exchange
Fierce Biotech
Circassia
IPOs
London
AIM
Flag link:
Nasdaq celebrates record biotech IPO success in 2018. But can the party on Wall Street rumba on?
Nasdaq celebrates record biotech IPO success in 2018. But can the party on Wall Street rumba on?
Endpoints
IPOs
biotech
NASDAQ
Flag link:
Moderna, largest biotech to go public, fails to impress in market debut
Moderna, largest biotech to go public, fails to impress in market debut
Reuters
IPOs
biotech
Moderna Therapeutics
Flag link:
DiaMedica pulls off IPO to fund midphase stroke trial
DiaMedica pulls off IPO to fund midphase stroke trial
Fierce Biotech
IPOs
DiaMedica Therapeutics
chronic kidney disease
acute ischemic stroke
Flag link:
Moderna Raises $604M and Nails Down Biotech’s Biggest IPO Ever
Moderna Raises $604M and Nails Down Biotech’s Biggest IPO Ever
Xconomy
IPOs
Moderna Therapeutics
Flag link:
ViaCyte Raises $80M to Prep for the Clinic Now, Perhaps an IPO Later
ViaCyte Raises $80M to Prep for the Clinic Now, Perhaps an IPO Later
Xconomy
ViaCyte
stem cells
diabetes
IPOs
clinical trials
Flag link:
Can a $1B IPO attract leery investors on HKEX? WuXi AppTec is set to find out
Can a $1B IPO attract leery investors on HKEX? WuXi AppTec is set to find out
Endpoints
IPOs
Hong Kong
WuXi AppTec
Flag link:
Can a biotech unicorn break into the record books with a $600M IPO? Stéphane Bancel has a fortune riding on the answer
Can a biotech unicorn break into the record books with a $600M IPO? Stéphane Bancel has a fortune riding on the answer
Endpoints
Moderna
biotech
IPOs
Stephane Bancel
Flag link:
The flip side of the hot IPO market? A chill could trigger a sudden cash crunch in biotech, followed by more deals
The flip side of the hot IPO market? A chill could trigger a sudden cash crunch in biotech, followed by more deals
Endpoints
biotech
IPOs
Flag link:
Genfit plans US listing as NASH drugmakers race to the finish line
Genfit plans US listing as NASH drugmakers race to the finish line
Endpoints
Genfit
IPOs
NASH
Flag link:
Centrexion steps back from IPO amid volatile market
Centrexion steps back from IPO amid volatile market
BioCentury
Centrexion
IPOs
Flag link:
Preclinical biotech Synthorx wants a $100M IPO
Preclinical biotech Synthorx wants a $100M IPO
Fierce Biotech
IPOs
biotech
Synthorx
immuno-oncology
cytokines
Flag link:
Vapotherm prices $56m IPO
Vapotherm prices $56m IPO
Mass Device
Vapotherm
IPOs
devices
Flag link:
Moderna aims to raise $500 million in biotech’s largest-ever public offering
Moderna aims to raise $500 million in biotech’s largest-ever public offering
Stat
Moderna Therapeutics
IPOs
biotech
Flag link:
BIO Celebrates 300 Biotech IPOs since Enactment of the JOBS Act
BIO Celebrates 300 Biotech IPOs since Enactment of the JOBS Act
Biotech Now
JOBS Act
IPOs
biotech
Flag link:
Themis pulls out of IPO, looks into 'strategic options' to fund phase 3 vaccine trial
Themis pulls out of IPO, looks into 'strategic options' to fund phase 3 vaccine trial
Fierce Biotech
Themis Bioscience
IPOs
Amsterdam
chikungunya virus
Flag link:
Twist Bioscience IPO: What Investors Need to Know
Twist Bioscience IPO: What Investors Need to Know
Motley Fool
DNA sequencing
Twist Bioscience
IPOs
Flag link:
Gamida Cell raises $50M in NASDAQ IPO
Gamida Cell raises $50M in NASDAQ IPO
BioCentury
Gamida Cell
IPOs
NASDAQ
cell therapy
Flag link:
Hong Kong IPO delivers $421M to Innovent — fourth listed biotech in six months
Hong Kong IPO delivers $421M to Innovent — fourth listed biotech in six months
Endpoints
Hong Kong
IPOs
biotech
Innovent Biologics
Flag link:
Si-Bone closes $124m IPO
Si-Bone closes $124m IPO
Mass Device
SI-BONE
IPOs
devices
Flag link:

Pages